![]() This certainly highlights volatility within the biotech industry which is often characterized by high levels of uncertainty due to the complexity of biological systems and novel technologies used for drug development. These figures come in light of a recent purchase by major shareholder Global Investors Lp Viking who bought 850,000 shares in one transaction for approximately $16 per share totaling $13.6m on May 9th. However, despite this downgrade, 4D Molecular Therapeutics maintains an average rating of “Moderate Buy” amongst analysts and a $34.13 price target. The Q2 earnings per share (EPS) estimate for the company has been revised to ($0.89), with FY2023 earnings at ($3.57) EPS and predictions up to FY2027 reaching as low as ($5.13) EPS. 4D Molecular Therapeutics Faces Downgrade but Remains a Moderate Buy: Navigating Volatility in the Biotech Industryīiotech company, 4D Molecular Therapeutics (NASDAQ: FDMT), has been downgraded by market research firm, HC Wainwright. With institutional investors and hedge funds continuing to invest in 4D Molecular Therapeutics, there is no doubt that this company is here to stay. Still, the biotech firm’s commitment to developing innovative gene therapy products makes it a promising investment for those seeking long-term growth opportunities in this lucrative industry. In conclusion, 4D Molecular Therapeutics’ Q1 earnings results may have disappointed some investors. ![]() Its beta stands at 2.51 while its moving averages over 50 and 200 days come in at $17.54 and $18.92, respectively. The Company uses its proprietary Adeno-associated virus (AAV) vector discovery technology to create highly targeted and efficient vectors with distinct tissue tropisms for specific genetic diseases.Īt present, 4D Molecular Therapeutics’ stock price sits at $17.91 per share with a market cap of $576.63 million and a price-to-earnings ratio of -5.39 times earnings per share (EPS). One notable example is Candriam S.C.A., which recently acquired a new stake in 4D Molecular Therapeutics worth approximately $3,718,000.Īnother reason why investors remain bullish on 4D Molecular Therapeutics is due to its innovative approach to gene therapy development. These numbers indicate that 4D Molecular Therapeutics struggled in Q1 but should not be seen as indicative of its long-term potential.ĭespite these challenges, institutional investors and hedge funds continue to invest in 4D Molecular Therapeutics because they recognize the immense potential and long-term value that this company can bring to their portfolios. The company also reported an EPS of ($0.84), missing the consensus estimate of ($0.75) by ($0.09). Recently, 4D Molecular Therapeutics (NASDAQ: FDMT) announced its Q1 earnings results on Wednesday, March 15th.Īccording to the report, the company’s revenue for the quarter was $1.25 million, which was lower than consensus estimates of $4.97 million. One such company is 4D Molecular Therapeutics, a clinical stage biopharmaceutical company committed to developing gene therapy products for serious genetic diseases. Within this industry, there are some companies that stand out from the rest. The biotech industry is one of the most exciting sectors in the stock market. ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |